NDAORALFOR SUSPENSION
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLYCILLIN is an oral suspension formulation of ampicillin/ampicillin trihydrate, a beta-lactam antibiotic indicated for bacterial infections. As a broad-spectrum penicillin-class agent, it inhibits bacterial cell wall synthesis across a range of gram-positive and gram-negative organisms. This NDA product is currently in pre-launch stage under Bristol Myers Squibb sponsorship.
Pre-Launch
Pre-launch stage indicates lean commercial infrastructure; career opportunities will expand significantly post-approval, with emphasis on brand building and market penetration teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on POLYCILLIN at pre-launch offers entry or mid-career opportunity in antibiotic portfolio management and generic/established product commercialization at Bristol Myers Squibb. Success will require strategic positioning against generic competitors and focus on formulation/access differentiation rather than novel mechanism innovation.
Brand ManagerField Sales Representative
Worked on POLYCILLIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.